To improve the actions available to eligible product developers in the event of delays in receiving covered product for purposes of generic drug or biosimilar biological product development.
About This Bill
Committee
Latest Action · March 30, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.